II. Indications
-
Bacterial Coverage
- Multidrug-resistant Staphylococcus aureus
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant VISA
- Vancomycin-Resistant Staphylococcus aureus)
- StreptococcusPneumonia
- Includes drug-resistant strains
- Respiratory Gram-Negative Bacteria (including Beta-Lactamase-positive Bacteria)
- Multidrug-resistant Staphylococcus aureus
- Conditions
III. Mechanism
- Ceftaroline Fosamil is infused and hydrolyzed to the active form, Ceftaroline
- Inactivates Penicillin-binding Proteins on the inner membrane of the Bacterial cell wall (similar to other beta lactams)
- Interferes with cross-linkage of peptidoglycan chains, reducing Bacterial cell wall strength and rigidity
IV. Dosing: Adult
- Standard Dosing
- Give 600 mg IV every 12 hours infused over 5 to 60 minutes
-
Renal Dosing
- eGFR 31 to 50 ml/min: 400 mg IV every 12 hours
- eGFR 15 to 30 ml/min: 300 mg IV every 12 hours
- eGFR <15 or Hemodialysis: 200 mg IV every 12 hours
V. Dosing: Child
- Age 2 months to 2 years
- Give 8 mg/kg IV every 12 hours
- Age >2 years and weight <33 kg
- Give 12 mg/kg IV every 8 hours
- Age >2 years and weight >33 kg (Adult dosing)
- Give 400 mg IV every 8 hours OR
- Give 600 mg IV every 12 hours
VI. Pharmacokinetics
- Ceftaroline Fosamil is hydrolyzed to the active form, Ceftaroline in vivo
- Elimination Half-Life: 3 hours
VII. Adverse Effects
- Hemolytic Anemia (rare)
VIII. Safety
- Pregnancy Category B
- Considered safe in Lactation
IX. Resources
X. References
- Steed (2010) Pharmacotherapy 30(4):375-89 +PMID: 20334458